- €130.98bn
- €118.55bn
- $62.58bn
- 80
- 85
- 71
- 95
Annual cashflow statement for Pfizer, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | 10-K | 10-K | 10-K | 10-K | |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | 22,025 | 31,407 | 2,158 | 8,062 | — |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -3,147 | 1,016 | 5,868 | 2,836 | — |
| Discontinued Operations | |||||
| Extraordinary Items | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 12,804 | -4,456 | -2,174 | -3,065 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 32,580 | 29,267 | 8,700 | 12,744 | — |
| Capital Expenditures | -2,711 | -3,236 | -3,907 | -2,909 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -19,835 | -12,547 | -28,371 | 5,561 | — |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -22,546 | -15,783 | -32,278 | 2,652 | — |
| Financing Cash Flow Items | 16 | -335 | -632 | -469 | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -9,816 | -14,834 | 26,066 | -17,140 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 159 | -1,515 | 2,448 | -1,810 | — |